All Articles

Biotech firm Protara Therapeutics is making strides with a promising cell therapy for non-muscle invasive bladder cancer and a unique treatment for a critical nutrient deficiency in patients on long-term parenteral support, bolstering its financial outlook.

Brainomix’s AI stroke imaging solution is revolutionizing care, dramatically improving patient outcomes and accelerating access to life-saving treatment, according to new data.

Private equity-backed Valor Exterior is rapidly consolidating the Northeast’s fragmented roofing and home improvement market, fueling growth through strategic acquisitions and focusing on customer satisfaction.

Israeli medtech firm Nurami Medical receives FDA clearance for its innovative dural repair graft, ArtiFascia®, and secures significant funding, positioning it for growth in the $2 billion+ global dural repair market.

South University has appointed Benjamin J. DeGweck as its new CEO and Chancellor, tasking the legal veteran with stabilizing the for-profit institution amid ongoing financial scrutiny and a recent accreditation review.

Cabaletta Bio’s innovative CAR-T cell therapy for autoimmune diseases is demonstrating encouraging clinical results, but the biotech faces significant financial challenges that cast a shadow over its future.

Data anomalies in a key clinical trial have sent Jasper Therapeutics’ stock plummeting and forced a dramatic refocus of its pipeline. A deep dive into the challenges and potential path forward.

CRISPR Therapeutics is pushing beyond its approved therapies with promising data in Alpha-1 Antitrypsin Deficiency, cardiovascular disease, and thrombosis. A closer look at the science and strategy.

Facing a critical funding crunch, Bluejay Diagnostics is pushing forward with a rapid sepsis diagnostic test, hoping to disrupt a market ripe for innovation but crowded with competition. Can they deliver before time – and money – runs out?

Matador Technologies secures $10M for Bitcoin acquisition, fueling ambitious growth plans but raising concerns about shareholder dilution and crypto market fluctuations.

Facing financial headwinds, OneMedNet launches an AI-driven real-world data platform in partnership with Palantir, aiming to unlock recurring revenue and transform healthcare insights. Can this shift turn the tide?

Indonesia's OCBC bank is rolling out a new feature allowing customers to make contactless payments directly from their smartphones. This innovation aims to bolster digital payment adoption in a rapidly growing market.

Global language & AI solutions provider TransPerfect enters the rapidly growing Saudi market, fueled by Vision 2030 and a surging demand for localized content and advanced technologies.

The FEI General Assembly in Hong Kong highlights a shift towards digital innovation and horse welfare, positioning the region as a rising force in global equestrian sport. Investment & education are key.

A historic Manitoba mine is poised for a comeback, fueled by a $300K grant and a collaborative approach with local First Nations. Can this project spark a new era of responsible resource development?

ADC Therapeutics has bolstered its financial position with a $60M financing, allowing it to double down on commercializing ZYNLONTA and advancing key clinical trials, despite recent revenue headwinds. The company's strategic pivot signals a focus on maximizing its lead asset.

Wave Life Sciences is making strides in metabolic and rare disease treatment with its innovative RNA-based therapies, but faces a crowded field and increasing financial scrutiny as it charts its path to commercialization.

PayPal enters Canada's booming ‘Buy Now, Pay Later’ market with a unique offering: zero fees for consumers. Will this disrupt established players and change how Canadians shop?

Galecto’s acquisition of Damora Therapeutics, backed by a significant funding round, signals a promising advancement in targeted therapies for Myeloproliferative Neoplasms driven by the CALR mutation. The deal highlights a novel biotech launchpad model.

Pharvaris is making waves in the Hereditary Angioedema (HAE) treatment landscape with its oral therapy, deucrictibant, showing strong efficacy and a favorable safety profile in late-stage trials. Could this be the breakthrough patients have been waiting for?